From the American Academy of Ophthalmology

Investigators randomized in a double-masked fashion 30 patients with severe nonproliferative diabetic retinopathy or non–high-risk proliferative, to 50 mg of doxycycline monohydrate or placebo daily for 24 months. As early as six months after treatment, treatment resulted in significantly improved mean foveal sensitivity, as measured by frequency doubling perimetry (P = .04), and this significant difference persisted at 12 and 24 months.  They conclude that oral doxycycline may be a promising therapeutic strategy targeting the inflammatory component of diabetic retinopathy. JAMA Ophthalmology, May 2014